RUNX1 and acute lymphoblastic leukemia: Considering the differences in prognosis, treatment response, and known activation of kinase signaling in Ph-like B-ALL versus ETV6::RUNX1 B-ALL, we felt that a comparison of these subtypes would serve as a strong proof of concept to explore the value of a multi-omic approach to characterizing subtype-specific mechanisms.